Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 824.6 INR -0.17%
Market Cap: 829.7B INR

Zydus Lifesciences Ltd
Investor Relations

Zydus Lifesciences Ltd., a resilient player in India's pharmaceutical industry, traces its origins back to 1952, when it was founded in Ahmedabad. Over the decades, it has metamorphosed from a modest venture into a global healthcare presence, with a diverse repertoire that spans across pharmaceuticals, animal health, and consumer wellness products. The company's ethos is deeply embedded in innovation, steadfastly pursuing research and development to propel its pipeline of generics, novel therapeutics, and vaccines. With a robust manufacturing infrastructure spread across continents, Zydus ensures seamless distribution and availability of its products, thereby maintaining a key foothold in both established and emerging markets.

The lifeblood of Zydus's profitability streams from its comprehensive product portfolio, catering to a myriad of therapeutic areas such as cardiology, gastroenterology, and women's health, among others. It generates revenue primarily through the sale of branded generics and active pharmaceutical ingredients (APIs). Strategic alliances and collaborations further bolster its growth trajectory, providing new avenues for market expansion and technological advancements. As the firm continues to navigate the complex landscape of global healthcare demands, it remains anchored to its core mission of delivering accessible and affordable healthcare solutions, ensuring that it not only sustains its economic pulse but also positively impacts countless lives worldwide.

Show more
Loading
ZYDUSLIFE
BSE Sensex 30

Earnings Calls

2025 Q3
Feb 5, 2025
Show Transcript
Previous
Next
Strong growth and profitability with key product launches ahead
2025 Q3
Feb 5, 2025

In the recent earnings call, Zydus showcased robust quarterly performance, posting a 17% rise in consolidated revenues to INR 52.7 billion. Their U.S. business grew 31% year-on-year, fueled by strategic new product launches, particularly in the sitagliptin franchise, which holds long-term government contracts. The EBITDA margin improved to 26.3%, while net profit surged 30% to INR 10.2 billion. Zydus is confidently projecting sustained growth in FY '25, with expectations of high single-digit growth for its U.S. operations. Additionally, the Consumer Wellness segment recorded a promising 13% revenue increase. Innovative product development remains a focal point for future success.

Show Full Analysis

Management

Dr. Sharvil Pankajbhai Patel
MD & Executive Director
No Bio Available
Dr. Ganesh Narayan Nayak
COO & Executive Director
No Bio Available
Mr. Punit Patel
President & CEO of America
No Bio Available
Mr. Nitinkumar Dalsukhray Parekh
Chief Financial Officer
No Bio Available
Mr. Arvind Bothra
Head of Investor Relations
No Bio Available
Mr. Dhaval Narendra Soni
Company Secretary & Compliance Officer
No Bio Available

Contacts

Address
GUJARAT
Ahmedabad
Zydue Tower, Satellite Cross Road
Contacts
+917926868100
www.zyduslife.com